Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Current knowledge about biomarkers of acute kidney injury in liver cirrhosis

Han Ah Lee, Yeon Seok Seo

Clin Mol Hepatol. 2022;28(1):31-46. Published online August 2, 2021

DOI: https://doi.org/10.3350/cmh.2021.0148

View: 6262 Download: 313 Web of Science: 11 Crossref: 12

Original Article

Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels

Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu

Clin Mol Hepatol. 2011;17(2):130-138. Published online June 23, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.2.130

View: 8696 Download: 83 Crossref: 18

Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis

Mi Yeon Chung, Dae Won Jun, Su Ah Sung

Clin Mol Hepatol. 2010;16(3):301-307. Published online September 30, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.3.301

View: 9514 Download: 72 Crossref: 19

1 |

Viewed By 5133	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4996	MAFLD: How is it different from NAFLD?
Viewed By 4893	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3598	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3570	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 67	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search